EFFICACY AND SAFETY OF BOTULINUM TOXIN TYPE A IN THE TREATMENT OF TRIGEMINAL NEURALGIA: A SYSTEMATIC REVIEW OF CLINICAL EVIDENCE
Authors:
- Michał DominMDMichał Domin
- Anita ZięBaAZAnita ZięBa
- Justyna CałkaJCJustyna Całka
- Mateusz TaranowiczMTMateusz Taranowicz
- Dominika ZdobylakDZDominika Zdobylak
- Karolina OllikKOKarolina Ollik
- Kamil HarenzaKHKamil Harenza
- Monika KowalskaMKMonika Kowalska
- Katarzyna ŚcibiszKŚKatarzyna Ścibisz
- Olga KowalczykOKOlga Kowalczyk
Open Access
- 27 March 2026
- journal article
- review article
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 4 (1(49))
Abstract
Trigeminal neuralgia (TN) is a severe neuropathic pain disorder characterized by recurrent unilateral, electric shock–like facial pain. The firstly chosen treatments are usually pharmacological therapies. Although, the usage of botulinum toxin (BTX) injections are investigated due to its high levels of safety and effectiveness and low rates of side effects at the same time. This systematic review is focused on an analysis of different studies to confirm the advantages of BTX in the case of TN. In this study there were taken into consideration some randomized controlled trials, prospective studies, open-label studies, and case reports. In total 25 studies were analyzed. The research was focused on the reduction of pain intensity, frequency of recurrence, contentment of patients and rate of side effects. The results showed that BTX-A treatment in TN can be an effective and safe option for the patients. The reduction of pain intensity and frequency of attacks was reported. The findings were supported by some placebo controlled groups. In some cases there was even achieved a complete remission of symptoms. The adverse effects were rare and generally mild and transient. The BTX treatment gave promising results but the long term efficiency should be still investigated. There is also a high need to perform some enlarged studies with standardized procedures of BTX injections which would include the placebo control groups. In conclusion the usage of BTX-A in NT treatment appears to be an effective and safe option and a great alternative to traditional pharmacological therapy.Keywords
This publication has 40 references indexed in Scilit:
- Botulinum toxin-A as a treatment option for refractory idiopathic trigeminal neuralgia of the ophthalmic branch: a case report and literature reviewOral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2024
- Neuromodulators for Atypical Facial Pain and Neuralgias: A Systematic Review and Meta‐AnalysisThe Laryngoscope, 2020
- A new target for the treatment of trigeminal neuralgia with botulinum toxin type ANeurological Sciences, 2017
- Intraoral administration of botulinum toxin for trigeminal neuropathic painOral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2016
- Botulinum toxin A, brain and painProgress in Neurobiology, 2014
- Use of botulinum toxin A for drug-refractory trigeminal neuralgia: preliminary reportOral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology, 2011
- Injection of botulinum toxin type A (BOTOX) into trigger zone of trigeminal neuralgia as a means to control painOral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology, 2010
- Subcutaneous Botulinum toxin type A reduces capsaicin-induced trigeminal pain and vasomotor reactions in human skinPain, 2009
- Review of a Proposed Mechanism for the Antinociceptive Action of Botulinum Toxin Type ANeuroToxicology, 2005
- Subcutaneous administration of botulinum toxin A reduces formalin-induced painPain, 2004